

Efficient and stereoselective synthesis of (*S*)- α -propargylglycine derivatives from allenylboronic acid

Veronika A. Morozova, Irina P. Beletskaya and Igor D. Titanyuk

Experimental

1. General

Nuclear magnetic resonance (^1H NMR, ^{13}C NMR) spectra were measured at 25 °C in an indicated solvent with Bruker AV-400 spectrometer or Agilent 400-MR spectrometer. ^1H and ^{13}C NMR spectra were recorded at 400 MHz and 100 MHz respectively. The proton chemical shifts are reported in ppm from the residual proton signal of solvent. High resolution mass spectra (HRMS) were measured on a Bruker maXis instrument using electrospray ionization (ESI). IR spectra were recorded with the Specord UR-20 infrared spectrometer. Optical rotation values recorded using VNIIEKI Prodmash polarimeter. Analytical thin layer chromatography (TLC) was performed on Silica gel 60 F₂₅₄ Plates (Merck, 0.25 mm thickness). Silica gel column chromatography was performed using Silica 60 (Macherey-Nagel, 0.040 – 0.063 mm) using indicated solvent systems. Reagents were purchased from commercial supplier (Sigma-Aldrich) and were used without further purification. Benzyl azide (0.5 M sln in CH₂Cl₂) was purchased from Sigma-Aldrich. Starting azides explored for preparation of conjugates **8** and **10** were synthesized according to published procedures^[S1,S2]. 5-(4-azidophenyl)-10,20-bis(4-*tert*-butylphenyl)-15-mesitylporphyrin zinc was a gift of Dr. V. S. Tyurin (Frumkin Institute of physical chemistry and electrochemistry).

Anhydrous dichloromethane was prepared by distillation from calcium hydrate. Anhydrous diethyl ether was prepared by distillation from sodium.

2. Preparation of allenylboronic acid (**1**)

2.1. Allenylmagnesium bromide

In a three-necked flask equipped with a reflux condenser, propargyl bromide (0.36 g, 2.4 mmol, 80% solution in toluene) was added to a mixture of Mg (1.1 g, 45 mmol) and HgCl₂ (32 mg, 0.117 mmol) in 60 ml of dry ether under argon atmosphere. The mixture was heated to 40 °C until bubbles began to release. Then the rest propargyl bromide (2.826 g, 19 mmol, 80% solution in toluene) was added to the reaction mixture in small portions. After the addition was complete, the mixture was stirred at room temperature for 1.5 hours until it became cloudy white. The resulting solution was decanted into another flask to get rid of excess Mg. **Important!** The solution of allenylmagnesium bromide is not stable during storage, it is necessary to use it immediately after preparation.

2.2. Allenylboronic acid

Freshly prepared allenylmagnesium bromide solution (60 ml in ether, ~ 20 mmol) and a solution of trimethyl borate (2.78 g, 26.7 mmol) in ether (30 ml) were added simultaneously, but separately, over 1 h period to 25 ml of ether maintained at -78 °C. The mixture was stirred at -78 °C for more 2 h (heavy precipitate was formed) and then was warmed to 0 °C, when cold HCl (2 M aq., 40 ml) was added. The two-phase mixture was stirred at room temperature for 1 h and then the aqueous layer was extracted with Et₂O-CH₂Cl₂ solvent mixture (5:1, 3 x 20 ml). The combined extracts were dried (Na₂SO₄), filtered, and concentrated in vacuum to a volume about 20 ml (anhydrous, concentrated allenylboronic acid is unstable). The yield of boronic acid was not determined, therefore, for further reactions, it was conventionally assumed that all propargyl bromide was transformed into boronic acid.

3. 2-{*N*-[(*S*)-1-Phenylethyl]amino}pent-4-ynoic acid (4)

To a stirred solution of glyoxalic acid monohydrate (920 mg, 10 mmol) in CH₂Cl₂ (10 ml) (*S*)-1-phenylethylamine (1.212 g, 10 mmol) was added in one portion, and the solution stirred for 5 min. Then allenylboronic acid **7** (15 ml, 15 mmol, 1.5 equiv based on propargyl bromide used in the previous step) was added, and the reaction mixture was stirred vigorously at room temperature for 24 h. The precipitate was isolated by filtration and washed with ether (10 ml). The crude material gave good spectroscopic data, while ¹H-NMR indicated 81:19 *dr*. No additional purification required. White powder. Yield: 1.996 g (91%). Major diastereomer (*R,S*) (signals taken from mixture): ¹H NMR (methanol-d₄/D₂O, 400 MHz) δ: 7.55-7.35 (m, 5H), 4.51 (m, 1H), 3.53 (dd, *J*₁ = 4.7 Hz, *J*₂ = 7.0 Hz, 1H), 2.93-2.85 and 2.78-2.68 (m, 2H), 2.56 (m, 1H), 1.68 (d, *J* = 5.9 Hz, 3H); ¹³C NMR (methanol-d₄/D₂O, 100 MHz) δ: 184.1, 135.4, 129.5, 129.0, 128.0, 75.3, 74.0, 58.9, 56.1, 19.7, 18.3. Minor diastereomer (*S,S*) (signals taken from mixture): ¹H NMR (methanol-d₄, 400 MHz) δ: 7.55-7.35 (m, 5H), 4.43 (q, 1H, *J* = 6.0 Hz), 3.53 (dd, 1H, *J*₁ = 4.7 Hz, *J*₂ = 7.0 Hz), 2.93-2.85 and 2.78-2.68 (m, 2H), 2.50 (m, 1H), 1.61 (d, 3H, *J* = 5.9 Hz);

Analysis (mixture): Calcd for C₁₃H₁₅NO₂: C, 71.87; H, 6.96; N, 6.45; found: C, 71.68; H, 6.90; N, 6.53.

4. *N*-[(*S*)-(1-Phenylethyl)amino]pent-4-ynoic acid methyl ester (5)

To a stirred suspension of amino acid **4** (434 mg, 2 mmol) in methanol (5 ml), SOCl₂ (714 mg, 6 mmol) was added. The mixture was refluxed for 3 h and then stirred at room temperature for 12 h. pH was adjusted to ~9 with aqueous K₂CO₃. Excess of methanol was removed in vacuum and then the aqueous phase was extracted with ether (3 x 10-ml). The combined extracts were dried (Na₂SO₄), filtered, and concentrated in vacuum. Purification of the residue by column chromatography (EtOAc/petrol ether, 1:15 v/v) gave separated diastereomers (*R,S*)-**5** and (*S,S*)-**5** in a total yield 423 mg (89%). Major diastereomer: (*R*)-*N*-[(*S*)-(1-phenylethyl)amino]pent-4-ynoic acid methyl ester ((*R,S*)-**5**). Yellow oil. Yield 301 mg (63%).

[α]_D²⁰ = -44.9° (*c* 2.58, CHCl₃); ¹H NMR (CDCl₃, 400 MHz) δ: 7.31-7.23 (m, 5H), 3.86 (q, *J* = 6.5 Hz, 1H), 3.64 (s, 3H), 3.44 (t, *J* = 5.5 Hz, 1H), 2.58 (m, 2H), 2.14 (bs, NH), 2.04 (s, 1H), 1.37 (d, *J* = 6.6 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ: 173.5, 144.6, 128.5, 127.2, 126.8, 79.5, 71.1, 57.1, 55.8, 52.0, 23.8, 22.7; Analysis: Calcd for C₁₄H₁₇NO₂: C, 72.70; H, 7.41; N, 6.06; found: C, 72.46; H, 7.16; N, 6.31.

Minor diastereomer: (*S*)-*N*-[(*S*)-(1-phenylethyl)amino]pent-4-enoic acid methyl ester ((*S,S*)-**5**). Yellow oil. Yield 120 mg (25 %) contaminated with 30% (*R,S*) isomer. ¹H NMR (CDCl₃, 400 MHz) δ: 7.31-7.25 (m, 5H), 3.79 (q, *J* = 6.6 Hz, 1H), 3.74 (s, 3H), 3.21 (t, *J* = 5.8 Hz, 1H), 2.51 (m, 2H), 2.11 (bs, NH), 2.04 (s, 1H), 1.35 (d, *J* = 6.6 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ: 174.3, 144.7, 128.5, 127.2, 126.9, 79.5, 71.1, 57.1, 56.6, 51.9, 23.9, 22.8.

5. Cu^I-Catalyzed 1,3-dipolar cycloaddition of amino ester (*R,S*)-**5**. General Procedure

To a stirred solution of CuI (19 mg, 0.1 mmol, 0.1 eq.) and DIPEA (65 mg, 0.5 mmol, 0.5 eq.) in DMF (2 ml) amino ester (*R,S*)-**5** (231 mg, 1 mmol, 1 eq.) and corresponding azide (1 mmol, 1 eq) were added. The mixture was stirred at room temperature for 24 hours under argon atmosphere. Then 50 ml of water and 50 ml of ethyl acetate were added. The organic layer was separated; the aqueous layer was washed with 3 × 50 ml of ethyl acetate. The organic phases were combined, dried over MgSO₄ and concentrated in vacuum. Purification of the product was carried out by column chromatography on silica.

5.1. Methyl 3-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-*N*-[(*S*)-1-phenylethyl]-D-alaninate (**7**)

Obtained from (*R,S*)-**5** and benzyl azide. Chromatography: ethyl acetate/petrol ether 2:1 v/v. Yellow oil. Yield 324 mg (87%). [α]_D²⁰ = -19,7° (*c* 1,522, CHCl₃); IR (KBr): 702, 731, 1204, 1559, 1630, 1736, 3325; ¹H NMR (CDCl₃, 400 MHz) δ: 7.30-7.10 (m, 11H), 5.44 (s, 2H), 3.76 (dd, *J*₁ = 6.7 Hz, *J*₂ = 13.1 Hz, 1H), 3.61 (s, 3H), 3.38 (m, 1H), 2.95 (dd, *J*₁ = 4.6 Hz, *J*₂ = 9.9 Hz, 2H), 2.12 (bs, NH), 1.27 (d, *J* = 6.5 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ: 174.6, 144.9, 144.2, 135.0, 129.1, 128.7, 128.5, 127.9, 127.2, 126.8, 122.1, 58.6, 56.1, 54.0, 51.8, 29.2, 23.3. Analysis: Calcd for C₂₁H₂₄N₄O₂: C, 69.21; H, 6.64; N, 15.37; found: C, 69.07; H, 6.72; N, 15.14.

5.2. Methyl (2*R*)-3-(1-((3*aR*,5*S*,6*R*,6*aR*)-5-((*S*)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[2,3-*d*][1,3]dioxol-6-yl)-1*H*-1,2,3-triazol-4-yl)-2-((*S*)-1-phenylethylamino)propanoate (**8**)

Obtained from (*R,S*)-**5** and 3-azido-3-deoxy-1,2:5,6-bis(O,O-propylidene)-D-glucofuranose. Chromatography: ethyl acetate/petrol ether 2:1 v/v. Yellow oil. Yield 258 mg (50%). [α]_D²⁰ = +54.0° (*c* 0.28, CHCl₃); IR (KBr): 702, 764, 1217, 1552, 1603, 1736, 3300-3700; ¹H NMR (CDCl₃, 400 MHz) δ: 7.63 (s, 1H), 7.23 (m, 5H), 5.95 (m, 1H), 5.12 (m, 1H), 4.81 (m, 1H), 4.41 (m, 1H), 4.25 (m, 1H), 3.96 (m, 1H), 3.79 (m, 1H), 3.60 (m, 1H), 3.55 (s, 3H), 3.48 (m, 1H), 3.06 (m, 2H), 2.03 (bs, NH), 1.62 (s, 3H), 1.32 (s, 3H), 1.31 (s, 3H), 1.29 (s, 3H), 1.26 (d, *J* = 6.7 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ: 174.6, 144.9, 143.7, 128.5, 127.2, 126.8, 122.6, 113.6, 110.1, 104.2, 79.2, 78.0, 75.3, 65.6, 62.5, 58.6, 56.2, 51.8, 29.4, 26.7, 26.4, 26.2, 25.1, 23.3; Analysis: Calcd for C₂₆H₃₆N₄O₇: C, 60.45; H, 7.02; N, 10.85; found: C, 60.54; H, 7.18; N, 10.92.

5.3. Compound **9**

To a stirred solution of CuI (3.8 mg, 0.02 mmol) and DIPEA (3 mg, 0.023 mmol) in THF/CH₃CN (5:1, 1 ml) amino ester (*R,S*)-**5** (10 mg, 0.043 mmol, 1.26 eq) and 5-(4-azidophenyl)-15-(4-*tert*-butylphenyl)-10,20-dimesitylporphyrin zinc (30 mg, 0.034 mmol, 1 eq) were added. The mixture was stirred at 60 °C for 3 h and at room temperature for 24 hours under argon atmosphere. The solvents were evaporated in vacuum. Purification of the product was carried out by column chromatography on silica using CH₂Cl₂, then ethyl acetate/petrol

ether 2:1 v/v. Red solid. Yield 26 mg (69%). $[\alpha]_D^{20} = -114.3^\circ$ (c 0.04, CH₃OH); ¹H NMR (CDCl₃, 400 MHz) δ : 8.80 (d, $J = 1.5$ Hz, 4H), 8.73 (s, 4H), 8.30 (m, 2H), 7.79 (m, 3H), 7.31-7.22 (m, 14H), 3.83-3.58 (m, 3H), 3.55 (s, 3H), 3.35 (m, 1H), 2.64 (s, 6H), 2.63 (s, 3H), 2.35 (bs, NH), 1.88 (s, 6H), 1.86 (s, 12H), 1.32 (d, $J = 6.6$ Hz, 3H); IR (KBr): 734, 805, 1005, 1540, 1615, 1746; MS (MALDI-TOF) m/z : 1074 ($[M-CH_3]^+$).

5.4. Methyl 2-(*tert*-butoxycarbonylamino)-3-(4-((*R*)-3-methoxy-3-oxo-2-((*S*)-1-phenylethylamino)propyl)-1*H*-1,2,3-triazol-1-yl)propanoate (10)

Obtained from (*R,S*)-**5** and racemic methyl 3-azido-2-(*N*-Boc-amino)propionate.


Chromatography: ethyl acetate/petrol ether 1:2 v/v, then pure ethyl acetate. Colorless oil. Yield 351 mg (74%). IR (KBr, 1:1 diastereomeric mixture): 704, 764, 1167, 1504, 1600, 1716, 1734; ¹H NMR (CDCl₃, 400 MHz, 1:1 diastereomeric mixture) δ : 7.35 (d, $J = 6.0$ Hz, 1H), 7.29-7.20 (m, 4H), 7.12-7.19 (m, 1H), 5.40 (bs, NH), 4.72 (m, 3H), 3.78 (m, 1H), 3.73 (s, 3H), 3.58 (m, 1H), 3.53 (s, 3H), 3.07 (dd, $J_1 = 5.9$ Hz, $J_2 = 14.9$ Hz, 1H), 2.97 (dd, $J_1 = 6.2$ Hz, $J_2 = 14.9$ Hz, 1H), 2.13 (bs, NH), 1.41 (s, 9H), 1.29 (d, $J = 2.7$ Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz, 1:1 diastereomeric mixture) δ : 174.4, 169.5, 144.9, 143.7, 128.5, 127.2, 126.7, 123.3, 80.6, 58.4, 56.1, 56.0, 53.7, 53.0, 51.8, 50.9, 50.8, 29.0, 28.9, 28.2, 23.4; Analysis: Calcd for C₂₃H₃₃N₅O₆: C, 58.09; H, 6.99; N, 14.73; found: C, 85.21; H, 7.08; N, 14.40.


References

- S1. D. Shetty, J. M. Jeong, C. H. Ju, Y. J. Kim, J.-Y. Lee, Y.-S. Lee, D. S. Lee, J.-K. Chung and M. C. Lee, *Bioorg. Med. Chem.*, 2010, **18**, 7338.
- S2. A-P. Wang, C. Liu, S. Yang, Z. Zhao and P. Lei, *Tetrahedron*, 2016, **72**, 285.


^1H and ^{13}C NMR spectra of compounds


N-[(*S*)-1-phenylethyl]pentynoic acid (**4**)[dr 81:19]($\text{CD}_3\text{OD}/\text{D}_2\text{O}$)







(R)-*N*-[*(S)*-(1-phenylethyl)amino]pent-4-ynoic acid methyl ester (**(R,S)**-5) (CDCl₃)







(S)-*N*-[*(S)*-(1-phenylethyl)amino]pent-4-ynoic acid methyl ester (*(S,S)*-**5**) (contaminated with *(R,S)*-**5**)







Methyl 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-N-[(1S)-1-phenylethyl]-D-alaninate (7)






Methyl (2R)-3-(1-((3aR,5S,6R,6aR)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-yl)-1H-1,2,3-triazol-4-yl)-2-((S)-1-phenylethylamino)propanoate (8)







Compound 9



Compound 9 (selected regions)



Methyl 2-(tert-butoxycarbonylamino)-3-(4-((R)-3-methoxy-3-oxo-2-((S)-1-phenylethylamino)propyl)-1H-1,2,3-triazol-1-yl)propanoate (10)

